KINAXIS
12.3.2024 12:01:32 CET | Business Wire | Press release
Kinaxis (TSX:KXS), the global leader in supply chain orchestration, and a pioneer in artificial intelligence (AI) and machine learning (ML), has been laying the groundwork for continued success in the industry through a rapidly growing patent portfolio. Over the past five years, the company’s patent portfolio has grown by more than 500% and as of today, 55% of the portfolio is for AI and ML-based innovations.
The exponential growth comes as a direct result of significant investments in research and development as part of the company’s commitment to strengthen its leadership position as a trusted technology provider to chief supply chain officers globally. As part of a robust innovation program, Kinaxis continues rolling out a steady stream of AI- and ML-powered capabilities, which empower its 40,000 users to build the most intelligent supply chains on the planet.
Kinaxis uses AI innovation to drive better results while maintaining the speed and agility required to navigate modern supply chain challenges - by generating prescriptive recommendations, predicting and surfacing insights, automating processes and enhancing productivity through its platform. This human-centred approach puts people first, augmenting their capabilities to support faster and more informed decision making.
“Kinaxis has always been about making life easier for the people behind supply chains and the people they serve, and our patent portfolio is a strong indicator of our success innovating in this space,” said Chantal Bisson-Krol, vice president of AI & ML solutions at Kinaxis. “Our approach to innovating with AI/ML is no different. Our solutions are purpose-built, ensuring AI augments the people using it, so they can make decisions with more speed and accuracy. The recent AI patent growth we’ve seen demonstrates that this approach is working.”
“In an era where supply chains are increasingly complex and where agility, resilience, and sustainability are imperatives, the companies that best leverage AI/ML to enhance the capabilities of their supply chain teams will emerge as leaders,” said Tariq Farooq, former chief supply chain officer at Sanofi. “Kinaxis has a laser-like approach to pushing the boundaries of what’s possible and the growth of its AI/ML patent portfolio make it well-placed to support their client teams in their supply chain transformations.”
Pending and issued patents cover all aspects of Kinaxis technology, examples of which include:
- Dynamic Demand Sensing patents that provide better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. weather, shifts in consumer behavior, local/national events) are influencing short- and long-term demand for their products.
- Patents that significantly expedite the various tasks in a ML workflow, providing timely responses and insights for retail scale data.
Kinaxis’ AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps companies supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.
To learn more about Kinaxis and how it is transforming the way AI is used in supply chains, please visit https://www.kinaxis.com/en/artificial-intelligence
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312570571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP24.2.2026 14:00:00 CET | Press release
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/ Supporting stable, high-titer cell line development and seamless GMP advancement. The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and re
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 202624.2.2026 14:00:00 CET | Press release
-- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results from Phase 1b -- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA. The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative d
Axelera AI Secures More Than $250 Million Funding on Global Commercial Growth24.2.2026 14:00:00 CET | Press release
European AI semiconductor leader earns backing from funds managed by Innovation Industries and SiteGround Capital along with EU institutions; edge-first architecture addresses AI's critical energy and cooling constraints Axelera AI, the European leader in AI acceleration hardware, announced its latest funding round led by Innovation Industries, with participation from prominent funds and accounts including BlackRock and SiteGround Capital as new investors, as well as existing investors Bitfury, CDP Venture Capital, European Innovation Council Fund, Federal Holding and Investment Company of Belgium (SFPIM), Invest-NL, Samsung Catalyst Fund, and Verve Investments. Axelera AI has attracted over $450 million in equity, grants and venture debt since incorporating in July 2021. The largest investment ever in an EU AI semiconductor company comes as Axelera ships to its 500th global customer across physical AI and edge AI in industries including defense and public safety, industrial manufactur
ExaGrid Wins New Industry Award24.2.2026 14:00:00 CET | Press release
Tiered Backup Storage recognized in inaugural StorageNewsletter Awards ExaGrid®, the leader in Tiered Backup Storage, today announced that it has been honored with an award in the Secondary Storage category from the first annual StorageNewsletter Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224387048/en/ ExaGrid Tiered Backup Storage wins the award for Secondary Storage for the first annual StorageNewsletter Awards. The winners of the StorageNewsletter Awards were chosen by a seven-member jury who selected the vendors for each category. “A long-standing innovator, ExaGrid has played a key role in shaping a new era of secondary storage with its scale-out architecture. Originally built around HDDs, the platform now supports SSDs and continues to gain market share at a rapid pace, driven by a strong channel ecosystem and broad validation from numerous backup software vendors. Through continuous feature enhancements
Armis Launches Developer Portal to Help Global Organizations Operationalize Asset Intelligence24.2.2026 14:00:00 CET | Press release
Self-service hub empowers developers, customers and partners to build integrated solutions with Armis Centrix™ Armis, the cyber exposure management & security company, today announced the launch of the Armis Developer Portal. The centralized knowledge hub enables organizations to seamlessly integrate Armis’ comprehensive asset intelligence into their existing technology stacks. Developers, customers and partners can fuel their applications using the Armis API, transforming static asset inventories into real-time, actionable insights that drive innovation and automation. “True security is only possible through a unified, open ecosystem where data is not just collected but operationalized," said Nadir Izrael, CTO and Co-Founder at Armis. “The Armis Developer Portal provides more than just documentation; we are giving the developer and security community direct access to the world’s most robust asset intelligence. This empowers them to move beyond simple monitoring to an intelligent, proa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
